Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Bioconjugate Chemistry
|
May 29, 1999
Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties
D L Ladd, R Hollister, X Peng, et al.
AJNR. American Journal of Neuroradiology
|
January 9, 2016
Computational Identification of Tumor Anatomic Location Associated with Survival in 2 Large Cohorts of Human Primary Glioblastomas
T T Liu, A S Achrol, L A Mitchell, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
October 6, 1997
A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI
D L Rubin, K L Falk, M J Sperling, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
November 13, 2008
BioPortal: ontologies and data resources with the click of a mouse
M A Musen, Mark Musen, N H Shah, et al.
Investigative Radiology
|
July 20, 2000
Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA)
R I Grossman, D L Rubin, G Hunter, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
October 26, 2000
Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging
M Federle, J Chezmar, D L Rubin, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
July 10, 1999
A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis
W C Small, D DeSimone-Macchi, J R Parker, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
August 10, 2000
Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety)
M P Federle, J L Chezmar, D L Rubin, et al.
Physical Review Letters
|
November 5, 2023
Measurement of the Positive Muon Anomalous Magnetic Moment to 0.20 ppm
D P Aguillard, T Albahri, D Allspach, et al.
Physical Review Letters
|
September 22, 2025
Measurement of the Positive Muon Anomalous Magnetic Moment to 127 ppb
D P Aguillard, T Albahri, D Allspach, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Bioconjugate Chemistry
|
May 29, 1999
Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties
D L Ladd, R Hollister, X Peng, et al.
AJNR. American Journal of Neuroradiology
|
January 9, 2016
Computational Identification of Tumor Anatomic Location Associated with Survival in 2 Large Cohorts of Human Primary Glioblastomas
T T Liu, A S Achrol, L A Mitchell, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
October 6, 1997
A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI
D L Rubin, K L Falk, M J Sperling, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
November 13, 2008
BioPortal: ontologies and data resources with the click of a mouse
M A Musen, Mark Musen, N H Shah, et al.
Investigative Radiology
|
July 20, 2000
Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA)
R I Grossman, D L Rubin, G Hunter, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
October 26, 2000
Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging
M Federle, J Chezmar, D L Rubin, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
July 10, 1999
A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis
W C Small, D DeSimone-Macchi, J R Parker, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
August 10, 2000
Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety)
M P Federle, J L Chezmar, D L Rubin, et al.
Physical Review Letters
|
November 5, 2023
Measurement of the Positive Muon Anomalous Magnetic Moment to 0.20 ppm
D P Aguillard, T Albahri, D Allspach, et al.
Physical Review Letters
|
September 22, 2025
Measurement of the Positive Muon Anomalous Magnetic Moment to 127 ppb
D P Aguillard, T Albahri, D Allspach, et al.
Page
of 6